New Brunswick
-
Devices & Diagnostics, Pharma, BioPharma
J&J is latest big pharma, device company to call it splits with consumer health
Johnson & Johnson announced it plans to separate its consumer health products into a separate company, leaving the remaining business to focus on the more research-oriented pharmaceuticals and medical devices business segments. The announcement follows similar moves made by other large pharmaceutical and medical device companies.
-
J&J launches Phase III trial of single-shot Covid-19 vaccine
The placebo-controlled trial, ENSEMBLE, will enroll up to 60,000 healthy volunteers on three continents. The trial will test the vaccine JNJ-78436735, also known as Ad26.COV2.S.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
J&J to buy Momenta Pharmaceuticals for $6.5B
The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
-
J&J in $1B supply pact with federal government for one-shot Covid-19 vaccine
Under the agreement with BARDA and the Department of Defense, the drugmaker would supply 100 million doses of its vaccine, for which it published preclinical data last and is currently running a first-in-human clinical trial.
-
FDA approves subcutaneous version of J&J’s multiple myeloma drug
The company said Friday that it had received FDA approval for Darzalex Faspro, a version of the intravenous Darzalex designed for faster administration and that carries a better toxicity profile.
-
J&J HIV drug already in Covid-19 clinical trials flunks in vitro study
According to a preprint paper posted Tuesday, scientists at the company tested the drug, Prezista, against the virus in a cell culture, but found it had no activity. A combo therapy that includes Prezista’s active ingredient is in clinical trials in China.
-
J&J, HHS join forces on coronavirus vaccine as Moderna makes progress
J&J will work under an existing partnership with the department to develop a vaccine against COVID-19, while Moderna said it had produced the first batch of its own vaccine. Attendees at a recent biotech conference expressed concerns about the outbreak’s impact on drug manufacturing.
-
Report: J&J ‘pretty confident’ it can develop coronavirus vaccine, exec says
In an interview on CNBC’s “Squawk Box,” Paul Stoffels, the drugmaker’s chief scientific officer, said the company had started working on a vaccine two weeks ago, but it could take a year to reach the market.
-
Johnson & Johnson’s new antidepressant could face structural barriers to uptake
The FDA approved Spravato in March, but a new paper in JAMA examines some of the barriers inherent in the practice and reimbursement of psychiatry that could get in the way of widespread use of the drug.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
FDA approves Janssen’s Balversa for urothelial carcinoma – with a personalized medicine approach
The drug was approved along with a companion diagnostic to detect alterations in FGFR2 and FGFR3. The drug is approved for patients with locally advanced or metastatic UC who carry those mutations.
-
FDA approves J&J’s Spravato as first novel antidepressant in decades
The drug, a reformulation of ketamine, was approved for patients who have failed on other antidepressants. The original form of ketamine, approved as an anesthetic, has long been explored as a treatment for depression.
-
J&J to become first drugmaker to include list prices in DTC drug ads
In a post on its website by an executive, the company said it would begin including list price and out-of-pocket cost information for an anticoagulant later this quarter.
-
An open letter to J&J Chairman & CEO Alex Gorsky
Mr. Alex Gorsky needs to provide a more reasoned explanation for his decision to remain on President Trump’s American Manufacturing Council and what he can achieve even as five CEOs have departed following Mr. Trump’s response to Charlottesville.
-
So long, farewell, J&J won’t likely miss you…
Gary Pruden, worldwide chairman of medical devices at Johnson & Johnson steps down after 32 years at the company but his departure announcement comes sans the usual pat-on-back recognizing long service.